Zai Lab Limited

Zai Lab Limited is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an oral PARP inhibitor for ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for bacterial pneumonia and skin infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for hospital-acquired pneumonia caused by Acinetobacter baumannii; and Augtyro for ROS1-positive non-small cell lung cancer. The company also has strategic collaborations with partners such as Tesaro, NovoCure, Deciphera, Pfizer, and Amgen.

Zai Lab Limited is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol ZLAB. Its securities trade in US Dollars (USD). The company is headquartered in Pudong, China, but its shares are available to international investors through this US exchange, providing access to global capital markets.

Zai Lab operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it engages in research, development, and commercialization of innovative medicines. Its focus areas include oncology, immunology, neuroscience, and infectious diseases, leveraging both internal discovery and strategic partnerships to bring novel treatments to patients.

Zai Lab is headquartered in Pudong, China, and primarily serves the Chinese market along with global regions through its collaborations. The company was incorporated in 2013 and has built a portfolio of approved products addressing serious medical conditions. Its geographic focus includes China, but partnerships with international firms like Tesaro, NovoCure, and Pfizer allow it to access broader markets and technologies.

Zai Lab generates revenue through the commercialization of its approved pharmaceutical products. Key revenue drivers include Zejula for ovarian cancer, VYVGART for myasthenia gravis, NUZYRA for bacterial infections, Optune for glioblastoma, Qinlock for gastrointestinal stromal tumors, Xacduro for hospital-acquired pneumonia, and Augtyro for lung cancer. The company also benefits from strategic collaborations with partners such as Tesaro, NovoCure, Deciphera, Paratek, argenx, Turning Point Therapeutics, Entasis, Karuna, Pfizer, Amgen, and Boehringer Ingelheim, which may involve licensing fees, milestone payments, and profit-sharing.